Close Menu

NEW YORK – Greenwich LifeSciences said on Thursday that Baylor College of Medicine will serve as the lead site for a Phase III study evaluating its investigational immunotherapy, called GP2, for the prevention of breast cancer recurrence.

The Stafford, Texas-based drug developer is still working out the protocol of the study, in which researchers hope to explore the ability of GP2 to prevent recurrence in HER2-postive breast cancer patients who have undergone surgery. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.